Physical Health Monitoring for People with Schizophrenia

Overview

Journal Aust Prescr

Date 2023 Dec 28

PMID 38152317

Authors

David Castle

Amy Li

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a severe psychiatric disorder associated with significant comorbidities and early mortality. People with schizophrenia have a greater predisposition to the top 6 modifiable global mortality (cardiometabolic) risk factors as defined by the World Health Organization (compared with the general population). These are driven by genetic, lifestyle and disease factors, and obesogenic antipsychotic medications. Smoking, obesity and type 2 diabetes are the most important modifiable cardiometabolic risk factors for cardiovascular disease in people with schizophrenia. Enhanced physical health screening, especially for cardiometabolic risk factors, is recommended for people with schizophrenia. A multidisciplinary holistic approach is recommended for treating people with schizophrenia, using contact with primary care practitioners to review their physical health.

Citing Articles

Mendelian randomization analysis of causal and druggable circulating inflammatory proteins in schizophrenia.

Cao H, Fu L, Liu D, Baranova A, Zhang F Front Psychiatry. 2024; 15:1465291.

PMID: 39544374 PMC: 11560794. DOI: 10.3389/fpsyt.2024.1465291.

An Evaluation of a Women's Clinic: The Healthcare and Learning Project of the Functional Unit for Women with Schizophrenia.

Gonzalez-Rodriguez A, Natividad M, Palacios-Hernandez B, Ayesa-Arriola R, Cobo J, Monreal J Healthcare (Basel). 2024; 12(15).

PMID: 39120186 PMC: 11312130. DOI: 10.3390/healthcare12151483.

References

Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni A, Savage C . Cigarette Smoking by Patients With Serious Mental Illness, 1999-2016: An Increasing Disparity. Psychiatr Serv. 2017; 69(2):147-153. DOI: 10.1176/appi.ps.201700118. View

Kahn R, Fleischhacker W, Boter H, Davidson M, Vergouwe Y, Keet I . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618):1085-97. DOI: 10.1016/S0140-6736(08)60486-9. View

Morgan V, Waterreus A, Jablensky A, Mackinnon A, McGrath J, Carr V . People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012; 46(8):735-52. DOI: 10.1177/0004867412449877. View

Kishimoto T, De Hert M, Carlson H, Manu P, Correll C . Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012; 25(5):415-29. PMC: 3566242. DOI: 10.1097/YCO.0b013e328355e1ac. View

Mizuki Y, Sakamoto S, Okahisa Y, Yada Y, Hashimoto N, Takaki M . Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus. Int J Neuropsychopharmacol. 2020; 24(5):367-382. PMC: 8130204. DOI: 10.1093/ijnp/pyaa097. View

Lord O, Malone D, Mitchell A . Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. Gen Hosp Psychiatry. 2010; 32(5):519-43. DOI: 10.1016/j.genhosppsych.2010.04.004. View

Malhotra A, White D . Obstructive sleep apnoea. Lancet. 2002; 360(9328):237-45. DOI: 10.1016/S0140-6736(02)09464-3. View

Laursen T . Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011; 131(1-3):101-4. DOI: 10.1016/j.schres.2011.06.008. View

Kelly D, Wehring H, Earl A, Sullivan K, Dickerson F, Feldman S . Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013; 13:214. PMC: 3766216. DOI: 10.1186/1471-244X-13-214. View

10.

Mitchell A, Pereira I, Yadegarfar M, Pepereke S, Mugadza V, Stubbs B . Breast cancer screening in women with mental illness: comparative meta-analysis of mammography uptake. Br J Psychiatry. 2014; 205(6):428-35. DOI: 10.1192/bjp.bp.114.147629. View

11.

Yokoyama S, Wakamoto S, Tanaka Y, Nakagawa C, Hosomi K, Takada M . Association Between Antipsychotics and Osteoporosis Based on Real-World Data. Ann Pharmacother. 2020; 54(10):988-995. DOI: 10.1177/1060028020913974. View

12.

Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016; 50(5):410-72. DOI: 10.1177/0004867416641195. View

13.

Galletly C, Foley D, Waterreus A, Watts G, Castle D, McGrath J . Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012; 46(8):753-61. DOI: 10.1177/0004867412453089. View

14.

Stubbs B, Vancampfort D, Veronese N, Solmi M, Gaughran F, Manu P . The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis. J Affect Disord. 2016; 197:259-67. DOI: 10.1016/j.jad.2016.02.060. View

15.

Lahti M, Tiihonen J, Wildgust H, Beary M, Hodgson R, Kajantie E . Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med. 2012; 42(11):2275-85. DOI: 10.1017/S0033291712000396. View

16.

Castillo-Sanchez M, Fabregas-Escurriola M, Berge-Baquero D, Fernandez-SanMartin M, Goday-Arno A . Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?. Clin Exp Hypertens. 2017; 39(5):441-447. DOI: 10.1080/10641963.2016.1267200. View

17.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

18.

Al Lawati N, Patel S, Ayas N . Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. Prog Cardiovasc Dis. 2008; 51(4):285-93. DOI: 10.1016/j.pcad.2008.08.001. View

19.

Annamalai A, Tek C . An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol. 2015; 2015:969182. PMC: 4386295. DOI: 10.1155/2015/969182. View

20.

Byerly M, Suppes T, Tran Q, Baker R . Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007; 27(6):639-61. DOI: 10.1097/jcp.0b013e31815ac4e5. View